Latest Regulatory News

Macro Metals Limited is poised to resume trading on the ASX from July 18, 2025, following a key Supreme Court decision. The lifting of its trading suspension marks a significant regulatory milestone for the mining company.

Macro Metals Limited has obtained crucial Supreme Court orders to address a regulatory oversight involving cleansing notices, paving the way for the lifting of its trading suspension.

Vintage Energy has addressed an ASX compliance issue related to the timing of its May 2025 securities issuance, confirming reliance on its placement capacities to maintain regulatory adherence.

Raptis Group Limited has confirmed the resignation of director James Raptis effective September 30, 2025, amid a sharp rise in its share price and trading volume. The company denies any other undisclosed information behind the recent market activity.

MIXI Australia Pty Ltd has initiated an all-cash off-market takeover bid for PointsBet Holdings Limited at $1.20 per share, a significant premium recommended unanimously by the PointsBet Board. The offer promises certainty of cash consideration amid competing bids and regulatory conditions.

MIXI Australia has lodged a bidder’s statement for an all-cash $1.20 per share takeover offer for PointsBet Holdings Limited, with the PointsBet Board unanimously recommending acceptance in the absence of a superior proposal.

Silk Logistics Holdings has scheduled its shareholder meeting for August 1 to vote on the proposed $2.14 per share acquisition by DP World Australia, with an independent expert reaffirming the deal’s fairness.

Scalare Partners Holdings Limited has had its trading suspension lifted following its announcement of a capital raising to fund the acquisition of Tank Stream Labs.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

Australian Rare Earths (ASX, AR3) has responded to an ASX price query, denying any undisclosed price-sensitive information and attributing recent trading activity to sector interest and recent company announcements.

Clarity Pharmaceuticals has successfully completed recruitment for its pivotal Co-PSMA Phase II trial, testing its novel Cu-SAR-bisPSMA diagnostic against the current standard in detecting prostate cancer recurrence. This milestone advances their mission to improve early detection and treatment outcomes for men with low PSA levels.

Nova Minerals has closed a US$11.1 million underwritten offering on NASDAQ, positioning itself to advance exploration and feasibility studies at its Estelle Gold and Critical Minerals Project in Alaska.